Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18f]Fluoro-L-m-tyrosine

Journal of Cerebral Blood Flow and Metabolism

Volumn 19, Issue 3, 1999, Pages 278-287

  Doudet, D J ^a   Chan, G L Y ^a   Jivan, S ^b   Dejesus, O T ^a   McGeer, E G ^a   English, C ^a   Ruth, T J ^a   Holden, J E ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

6 18F L dopa; 6 18F L m Tyrosine; Dopamine neurons; Dopamine turnover; Positron emission tomography

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 6 FLUORODOPA F 18; DOPAMINE; TYROSINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; METABOLISM; MONKEY; NONHUMAN; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY;

EID: 0033398722     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004647-199903000-00006     Document Type: Article

References (23)

1. 18F]Fluoro-L-DOPA probes dopamine turnover rates in central dopaminergic structures. J Neurosci Res 27:487-493
2. Barrio JR, Huang SC, Yu DC, Melega WP, Quintana J, Cherry SR, Jacobson A, Namavari M, Satyamurthy N, Phelps ME (1996) Radiofluorinated L-m-tyrosines: new in vivo probes for central dopamine biochemistry. J Cereb Blood Flow Metab 16:667-678
3. Brooks D, Salmon EP, Mathias CJ, Quinn N, Leenders KL, Bannister R, Marsden CD, Frackowiak RSJ (1990) The relationship between locomotor disability, autonomic dysfunction and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure and Parkinson's disease, studied with PET. Brain 113:1539-1552
4. Chan GLY, Hewitt KA, Pate BD, Schofield P, Adam MJ, Ruth TJ (1992) Routine determination of [F18]-L-6-fluorodopa and its metabolites in blood plasma is essential for accurate positron emission tomography studies. Life Sci 50:309-318
5. 18F]6-fluoro-L-3,4-dihydroxyphenylalanine in the hooded rat. J Neurochem 48:601-608
6. DeJesus OT, Mukherjee J (1988) Radiobrominated m-tyrosine analog as a potential CNS L-DOPA PET tracer. Biochem Biophys Res Commun 150:1027-1031
7. DeJesus OT, Murali D, Nickles RJ (1995) Synthesis of brominated and fluorinated ortho-tyrosine analogs as potential DOPA decarboxylase tracers. J Label Comp Radiophann 37:147-149
8. DeJesus OT, Endres CJ, Shelton SE, Nickles RJ, Holden JE (1997) Evaluation of fluorinated m-tyrosine analogs as PET imaging agents for dopamine nerve terminals: comparison with 6-fluorodopa. J Nucl Med 38:630-636
9. Dhawan V, Ishikawa T, Patlak CS, Chaly T, Robeson W, Belakhlef A, Margouleff C, Mandel F, Eidelberg D (1997) Combined FDOPA and 3OMFD PET studies in Parkinson's disease. J Nucl Med 37:209-216
10. Doudet DJ, McLellan CA, Carson RE, Adams HR, Miyake H, Aigner TG, Finn RT, Cohen RM (1991) Distribution and kinetics of 3-O-methyl-6-[F18]fluoro-L-DOPA in the rhesus monkey brain. J Cereb Blood Flow Metab 11:726-734
11. Doudet DJ, Chan GLY, Holden JE, Morrison KS, Wyatt RJ, Ruth TJ (1997a) Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP-induced parkinsonism in monkeys. Neuropharmacology 36:363-371
12. Doudet DJ, Chan GLY, Holden JE, Pate BD, Morrison KS, Calne DB, Ruth TJ (1997b) Effects of MAO and COMT inhibition on the turnover of dopamine: a FDOPA PET study. Eur J Pharmacol 334:31-38
13. Doudet DJ, Chan GLY, Holden JE, Aigner TG, Wyatt RJ, Morrison KS, Ruth TJ (1998) 6-Fluoro-L-dopa PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys. Synapse 29:225-232
14. Endres CJ, Swaminathan S, Sievert M, Ruoho AE, DeJesus OT, Murali D, Rommelfanger SG, Holden JE (1997) Affinities of dopamine analogs for monoamine granular and plasma membrane transporters: implications in PET dopamine studies. Life Sci 60:2399-2406
15. 18F-fluoro-L-3,4-dihydroxyphenylalanine in the primate. J Neurochem 48:1077-1082
16. 18F]-fluoro-L-DOPA for the delineation of dopaminergic structures in the human brain. J Label Comp Radiopharm 30:272-273
17. 11C)-L-dopa following COMT inhibition: a study in vivo using positron emission tomography. J Neural Transm Gen Sect 87:15-22
18. Holden JE, Doudet DJ, Endres CJ, Chan GLY, Morrison KS, Vingerhoets FJG, Snow BJ, Pate BD, Sossi V, Buckley KR, Ruth TJ (1997) Extended graphical analysis of 6-fluoro-L-dopa trapping: effect of inhibition of catechol-O-methyltransferase on the rate of reversibility. J Nucl Med 38:1567-1574
19. Ishikawa T, Dhawan V, Chaly T, Robeson W, Belakhlef A, Mandel F, Dahl R, Margouleff C, Eidelberg D (1996) Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis. J Cereb Blood Flow Metab 16:854-863
20. 18F]Fluoro-L-m-tyrosine: metabolism, positron emission tomography kinetics, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lesions in primates. Brain Res 750:264-276
21. Laihinen A, Rinne JO, Rinne UK, Haaparanta M, Ruotsalainen U, Bergman J, Solin O (1992) [F18]-6-Fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462). Neurology 42:199-203
22. Martin WRW, Palmer MR, Patlak CS, Calne DB (1989) Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol 26:535-542
23. 18F]fluoro-L-dopa plasma input curves with and without carbidopa and in hemi-MPTP lesioned monkeys. Appl Radiat Isot 42:847-854